Literature DB >> 34876393

Pathologic Validation of Endoscopic Ablative Therapy for Gastric Epithelial Neoplasia: A Randomized Controlled Trial.

Cheal Wung Huh1, Jiyoung Kim2, Byung-Wook Kim3, Joon Sung Kim3.   

Abstract

BACKGROUND: The effectiveness of endoscopic ablative therapy such as monopolar coagulation (MC) or argon plasma coagulation (APC) have not been validated histologically. The aim of this study was the histologic validation of endoscopic ablative therapy for gastric epithelial neoplasia.
METHODS: We designed a prospective randomized controlled trial involving patients with gastric low-grade dysplasia. Patients were randomly assigned to either the APC or the MC group. Endoscopic ablative therapy was followed by endoscopic submucosal dissection (ESD) for histologic evaluation. The main outcome was histologic completeness of endoscopic ablative therapy.
RESULTS: Sixty-eight patients were recruited, of whom 34 patients underwent APC and 34 patients underwent MC followed by ESD. The APC group showed significantly higher complete eradication rate compared to the MC group (55.9% vs. 11.8%, P < .001). APC was the only significant predictor of histologic complete eradication in multivariate analysis (OR: 7.66; 95% CI: 2.139-27.448). No adverse events related to the procedure occurred in either group.
CONCLUSIONS: Although APC is a more effective treatment option than MC in the management of gastric epithelial neoplasia, the effectiveness of both methods was limited in eradicating gastric epithelial neoplasia completely. Therefore, endoscopic resection should be a first option for treatment of gastric epithelial neoplasia until the optimal method is established with further studies.

Entities:  

Mesh:

Year:  2021        PMID: 34876393      PMCID: PMC8975466          DOI: 10.5152/tjg.2021.20928

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.555


  26 in total

Review 1.  Gastric epithelial dysplasia.

Authors:  G Y Lauwers; R H Riddell
Journal:  Gut       Date:  1999-11       Impact factor: 23.059

Review 2.  Endoscopic ablation therapy for gastrointestinal superficial neoplasia.

Authors:  Naoki Muguruma; Koichi Okamoto; Tetsuo Kimura; Kazuhiro Kishi; Toshiya Okahisa; Seisuke Okamura; Tetsuji Takayama
Journal:  Dig Endosc       Date:  2011-12-29       Impact factor: 7.559

3.  Argon plasma coagulation for early gastric cancer: technique and outcome.

Authors:  Tadashi Kitamura; Satoshi Tanabe; Wasaburou Koizumi; Hiroyuki Mitomi; Katsunori Saigenji
Journal:  Gastrointest Endosc       Date:  2006-01       Impact factor: 9.427

4.  Ablation of residual gastric tumor by argon plasma coagulation after endoscopic resection.

Authors:  Sooyeon Oh; Sang Gyun Kim; Ji Min Choi; Eun Hyo Jin; Jee Hyun Kim; Jong Pil Im; Joo Sung Kim; Hyun Chae Jung
Journal:  Surg Endosc       Date:  2016-06-28       Impact factor: 4.584

5.  Outcomes of treatment of argon plasma coagulation therapy in elderly or high-risk patients with early gastric cancer: a comparison of outcomes among experienced and nonexperienced endoscopists.

Authors:  Toshihiko Tomita; Eitatsu Arai; Tomoaki Kohno; Takashi Kondo; Yongmin Kim; Tadayuki Oshima; Kazutoshi Hori; Jiro Watari; Takayuki Matsumoto; Hiroto Miwa
Journal:  J Clin Gastroenterol       Date:  2011-07       Impact factor: 3.062

6.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Endoscopy       Date:  2011-12-23       Impact factor: 10.093

7.  Argon plasma coagulation for successful treatment of early gastric cancer with intramucosal invasion.

Authors:  T Sagawa; T Takayama; T Oku; T Hayashi; H Ota; T Okamoto; H Muramatsu; S Katsuki; Y Sato; J Kato; Y Niitsu
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

8.  Argon plasma coagulation is safe and effective for treating smaller gastric lesions with low-grade dysplasia: a comparison with endoscopic submucosal dissection.

Authors:  Se Jin Jung; Soo-Jeong Cho; Il Ju Choi; Myeong-Cherl Kook; Chan Gyoo Kim; Jong Yeul Lee; Sook Ryun Park; Jun Ho Lee; Keun Won Ryu; Young-Woo Kim
Journal:  Surg Endosc       Date:  2012-10-18       Impact factor: 4.584

9.  Gastric dysplasia. A follow-up study.

Authors:  C Di Gregorio; P Morandi; R Fante; C De Gaetani
Journal:  Am J Gastroenterol       Date:  1993-10       Impact factor: 10.864

10.  Precancerous conditions and epithelial dysplasia in the stomach.

Authors:  B C Morson; L H Sobin; E Grundmann; A Johansen; T Nagayo; A Serck-Hanssen
Journal:  J Clin Pathol       Date:  1980-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.